Richard Baird
Cambridge University Hospitals · Breast Cancer Research Unit, University of Cambridge · Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Richard Baird as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:56 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT06188520 · A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsAstraZeneca · active not recruiting · ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC) · study chair
- Ph1NCT03616587 · Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.AstraZeneca · active not recruiting · ER+ HER2- Advanced Breast Cancer · principal investigator
- Ph2NCT03306472 · A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast CancerCambridge University Hospitals NHS Foundation Trust · completed · Breast Cancer · principal investigator
- N/ANCT02994511 · Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics TrialsCCTU- Cancer Theme · unknown · Cancer · principal investigator
- Ph1/Ph2NCT02768337 · Cambridge Brain Mets Trial 1Cambridge University Hospitals NHS Foundation Trust · terminated · Lung Cancer, Breast Cancer, Brain Cancer · principal investigator
- Ph1/Ph2NCT02285179 · Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside TamoxifenThe Netherlands Cancer Institute · completed · Breast Cancer · study chair
- Ph1/Ph2NCT01791985 · AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)Imperial College London · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:56 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.J Clin Oncol · 2011476 citationsRCR 11.0
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.Lancet Oncol · 2013445 citationsRCR 11.0
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.J Clin Oncol · 2020341 citationsRCR 14.1
- Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.Lancet Oncol · 2020314 citationsRCR 11.6
- First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors.Clin Cancer Res · 2015279 citationsRCR 7.8
- Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.Clin Infect Dis · 2016160 citationsRCR 7.3
- Antitumor activity in RAS-driven tumors by blocking AKT and MEK.Clin Cancer Res · 2015123 citationsRCR 3.1
- A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.Clin Cancer Res · 2013109 citationsRCR 2.7
- 77 citationsRCR 38.5
- Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.Clin Cancer Res · 201470 citationsRCR 1.8